{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:9756"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:9756","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Mesenchymal stromal cell therapy for liver fibrosis","abstract":"Substantial uncertainty exists from pre-clinical liver fibrosis models as to whether mesenchymal stromal cells (MSCs) are anti-fibrotic, and yet clinically they have been proposed as a putative anti-fibrotic therapy for patients. This research was set out to examine whether MSC therapy can reduce liver fibrosis. An assessment of the depth and persistence of fibrosis in two murine liver fibrosis models (12 doses of intraperitoneal carbon tetrachloride, or 16 weeks of oral thioacetamide) allowed a statistically powered analysis of MSC intervention. Human umbilical cord MSCs were peripherally injected after liver fibrosis was established, or during fibrogenesis. Finally, the effect of MSC conditioned medium on the biology of human stellate-cell line, LX2 cells, was examined. MSC administration neither resolved established fibrosis, nor abrogated fibrogenesis in either model. Peripherally injected MSCs were sequestered in the lungs. However, MSC conditioned medium attenuated the expression of collagen type-1 mRNA and promoted apoptosis in LX2 cells. The discordance between the in vivo and in vitro findings requires further exploration. Nevertheless, this statistically powered robust examination of human umbilical cord MSCs suggests no discernible anti-fibrotic influence in vivo, and future testing would require a significant deviation in protocol to overcome a documented barrier from this research.","abstract_html":"Substantial uncertainty exists from pre-clinical liver fibrosis models as to whether mesenchymal stromal cells (MSCs) are anti-fibrotic, and yet clinically they have been proposed as a putative anti-fibrotic therapy for patients. This research was set out to examine whether MSC therapy can reduce liver fibrosis. An assessment of the depth and persistence of fibrosis in two murine liver fibrosis models (12 doses of intraperitoneal carbon tetrachloride, or 16 weeks of oral thioacetamide) allowed a statistically powered analysis of MSC intervention. Human umbilical cord MSCs were peripherally injected after liver fibrosis was established, or during fibrogenesis. Finally, the effect of MSC conditioned medium on the biology of human stellate-cell line, LX2 cells, was examined. MSC administration neither resolved established fibrosis, nor abrogated fibrogenesis in either model. Peripherally injected MSCs were sequestered in the lungs. However, MSC conditioned medium attenuated the expression of collagen type-1 mRNA and promoted apoptosis in LX2 cells. The discordance between the in vivo and in vitro findings requires further exploration. Nevertheless, this statistically powered robust examination of human umbilical cord MSCs suggests no discernible anti-fibrotic influence in vivo, and future testing would require a significant deviation in protocol to overcome a documented barrier from this research.","abstract_has_math":false,"creators":["Haldar, Debashis"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2019,"date_issued":"2019-12","date_published":"2019-12","updated_at":"2026-11-19T09:30:54Z","subjects":["RB Pathology","RC Internal medicine"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/9756/7/Haldar2019PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A9756","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["wellcome_trust"]},{"key":"dc:creator","label":"Author","values":["Haldar, Debashis"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2019-12-13"]},{"key":"dc:date.issued","label":"Date","values":["2019-12"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/9756/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["RB Pathology","RC Internal medicine"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/9756/7/Haldar2019PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Substantial uncertainty exists from pre-clinical liver fibrosis models as to whether mesenchymal stromal cells (MSCs) are anti-fibrotic, and yet clinically they have been proposed as a putative anti-fibrotic therapy for patients. This research was set out to examine whether MSC therapy can reduce liver fibrosis. An assessment of the depth and persistence of fibrosis in two murine liver fibrosis models (12 doses of intraperitoneal carbon tetrachloride, or 16 weeks of oral thioacetamide) allowed a statistically powered analysis of MSC intervention. Human umbilical cord MSCs were peripherally injected after liver fibrosis was established, or during fibrogenesis. Finally, the effect of MSC conditioned medium on the biology of human stellate-cell line, LX2 cells, was examined. MSC administration neither resolved established fibrosis, nor abrogated fibrogenesis in either model. Peripherally injected MSCs were sequestered in the lungs. However, MSC conditioned medium attenuated the expression of collagen type-1 mRNA and promoted apoptosis in LX2 cells. The discordance between the in vivo and in vitro findings requires further exploration. Nevertheless, this statistically powered robust examination of human umbilical cord MSCs suggests no discernible anti-fibrotic influence in vivo, and future testing would require a significant deviation in protocol to overcome a documented barrier from this research."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Mesenchymal stromal cell therapy for liver fibrosis"]}]}],"canonical_facts":{"dc:contributor.sponsor":["wellcome_trust"],"dc:creator":["Haldar, Debashis"],"dc:date":["2019-12-13"],"dc:date.issued":["2019-12"],"dc:description.abstract":["Substantial uncertainty exists from pre-clinical liver fibrosis models as to whether mesenchymal stromal cells (MSCs) are anti-fibrotic, and yet clinically they have been proposed as a putative anti-fibrotic therapy for patients. This research was set out to examine whether MSC therapy can reduce liver fibrosis. An assessment of the depth and persistence of fibrosis in two murine liver fibrosis models (12 doses of intraperitoneal carbon tetrachloride, or 16 weeks of oral thioacetamide) allowed a statistically powered analysis of MSC intervention. Human umbilical cord MSCs were peripherally injected after liver fibrosis was established, or during fibrogenesis. Finally, the effect of MSC conditioned medium on the biology of human stellate-cell line, LX2 cells, was examined. MSC administration neither resolved established fibrosis, nor abrogated fibrogenesis in either model. Peripherally injected MSCs were sequestered in the lungs. However, MSC conditioned medium attenuated the expression of collagen type-1 mRNA and promoted apoptosis in LX2 cells. The discordance between the in vivo and in vitro findings requires further exploration. Nevertheless, this statistically powered robust examination of human umbilical cord MSCs suggests no discernible anti-fibrotic influence in vivo, and future testing would require a significant deviation in protocol to overcome a documented barrier from this research."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/9756/7/Haldar2019PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/9756/"],"dc:subject":["RB Pathology","RC Internal medicine"],"dcterms:accessrights":["public"],"dc:title":["Mesenchymal stromal cell therapy for liver fibrosis"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:30:54Z"}